Kenichi Ogiwara

This inventor holds 1 USPTO granted patent. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenichi Ogiwara. Retrieved from https://idiyas.com/inventor/kenichi-ogiwara-7hj7b00x

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kenichi Ogiwara: Innovator in Medicinal Composition

Introduction

Kenichi Ogiwara is a notable inventor recognized for his contributions to the field of medicinal compositions. His work focuses on innovative solutions for blood coagulation factor abnormalities, which are critical in medical treatments.

Latest Patents

Ogiwara holds a patent for a medicinal composition that is usable for preventing and/or treating blood coagulation factor IX abnormality. This composition comprises a multispecific antigen binding molecule that replaces the function of blood coagulation factor VIII. His innovative approach addresses significant medical challenges and offers potential therapeutic benefits.

Career Highlights

Kenichi Ogiwara is associated with Chugai Seiyaku Kabushiki Kaisha, a prominent company in the pharmaceutical industry. His role at the company has allowed him to contribute to groundbreaking research and development in medicinal therapies.

Collaborations

Due to space constraints, the details of his collaborations will not be included.

Conclusion

Kenichi Ogiwara's work exemplifies the impact of innovation in medicine, particularly in addressing blood coagulation disorders. His contributions continue to influence the field and pave the way for future advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…